Sun Pharma Advanced Research Company Limited

NSE: SPARC · Healthcare

Sun Pharma Advanced Research Company Limited Share Price & Analysis

224.52 -1.31%Updated 21 Jul 2026, 05:01 pm IST
LTP
224.52
-1.31%
Open
High
229.22
Low
221.55
Close
₹224.52
52W High
₹289
52W Low
₹108
Volume
1325K
Lot Size
1
Sector
Healthcare
Market Cap
₹8K Cr
Face Value
₹1
Mid Cap

Price Chart

Fundamentals

P/E
4.88
Sector P/E
54.4
P/B
4.95
EPS
₹47.86
ROE
279%
ROCE
164%
D/E Ratio
0.42
Div Yield
0%
Book Value
₹41.3
+

Strengths

  • Excellent return on equity (ROE 279%)
  • Efficient capital deployment (ROCE 164%)
  • Attractively valued vs sector (P/E 4.9x vs industry 54.4x)
  • Low debt relative to equity (D/E 0.4x)

Peer Comparison

CompanyCMPMkt CapP/EP/BROE %ROCE %D/E
SUNPHARMA
Sun Pharmaceutical Industries Limited
1,944
₹4.6L Cr37.35.591620.50.07
DIVISLAB
Divi's Laboratories Limited
7,388
₹1.9L Cr73.411.7116.5220.01
TORNTPHARM
Torrent Pharmaceuticals Limited
5,040
₹1.6L Cr73.620.3227.415.20.33
APOLLOHOSP
Apollo Hospitals Enterprise Limited
8,939
₹1.3L Cr64.913.5622.117.90.88
CIPLA
Cipla Limited
1,416
₹1.1L Cr30.13.3211.615.50.01
ZYDUSLIFE
Zydus Lifesciences Limited
1,123
₹1.1L Cr214.1721.221.10.38
LUPIN
Lupin Limited
2,405
₹1.1L Cr19.64.928.729.90.32

Showing 7 peers in the same sector · Sorted by market cap

Shareholding Pattern

SPARC · as of May 2026

Promoters65.67%0.01
FII1.47%0.02
DII0.97%0.16
Public31.88%0.12
CategoryMar 2025Jun 2025Sep 2025Dec 2025Mar 2026May 2026
Promoters65.68%65.68%65.68%65.68%65.68%65.67%
FII3.24%2.64%2.15%2.23%1.45%1.47%
DII0.67%0.17%0.21%0.64%1.13%0.97%
Public30.41%31.51%31.96%31.47%31.76%31.88%

Financials

Quarterly Results

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue
₹1.9K Cr
▲23062.5%
₹8 Cr
▲0.0%
₹8 Cr
▼20.0%
₹10 Cr
▼63.0%
₹27 Cr
▲80.0%
₹15 Cr
▲15.4%
₹13 Cr
▼23.5%
₹17 Cr
Op. Profit
₹1.8K Cr
▲3210.5%
₹-57 Cr
▲13.6%
₹-66 Cr
▼26.9%
₹-52 Cr
▲1.9%
₹-53 Cr
▲28.4%
₹-74 Cr
▲28.2%
₹-103 Cr
▼10.8%
₹-93 Cr
OPM
96.0%
▲114.3%
-670.0%
▲19.9%
-836.0%
▼54.8%
-540.0%
▼175.5%
-196.0%
▲60.3%
-494.0%
▲38.3%
-800.0%
▼44.1%
-555.0%
Net Profit
₹1.8K Cr
▲2301.3%
₹-80 Cr
▼5.3%
₹-76 Cr
▼46.2%
₹-52 Cr
▲13.3%
₹-60 Cr
▲25.0%
₹-80 Cr
▲25.2%
₹-107 Cr
▼11.5%
₹-96 Cr
EPS (₹)
54.27
▲2288.3%
-2.48
▼6.0%
-2.34
▼46.2%
-1.6
▲13.0%
-1.84
▲24.9%
-2.45
▲26.0%
-3.31
▼11.8%
-2.96

Values in ₹ Cr · Source: Screener.in

Annual Profit & Loss

MetricMar 2026Mar 2025Mar 2024Mar 2023
Revenue
₹1.9K Cr
▲2509.7%
₹72 Cr
▼5.3%
₹76 Cr
▼68.2%
₹239 Cr
Expenses
₹280 Cr
▼29.1%
₹395 Cr
▼17.4%
₹478 Cr
▲5.5%
₹453 Cr
Op. Profit
₹1.6K Cr
▲595.0%
₹-323 Cr
▲19.7%
₹-402 Cr
▼87.9%
₹-214 Cr
OPM
85.0%
▲118.9%
-450.0%
▲15.4%
-532.0%
▼491.1%
-90.0%
Other Income
₹-1 Cr
▼150.0%
₹2 Cr
▼93.1%
₹29 Cr
▲163.6%
₹11 Cr
Interest
₹34 Cr
▲277.8%
₹9 Cr
▲350.0%
₹2 Cr
▼75.0%
₹8 Cr
Depreciation
₹10 Cr
▼16.7%
₹12 Cr
▼7.7%
₹13 Cr
▲8.3%
₹12 Cr
PBT
₹1.6K Cr
▲552.8%
₹-343 Cr
▲11.4%
₹-387 Cr
▼73.5%
₹-223 Cr
Tax %
0.0%
0.0%
0.0%
0.0%
Net Profit
₹1.6K Cr
▲552.8%
₹-343 Cr
▲11.4%
₹-387 Cr
▼73.5%
₹-223 Cr
EPS (₹)
47.86
▲553.6%
-10.55
▲11.6%
-11.93
▼73.9%
-6.86
Div Payout
0.0%
0.0%
0.0%
0.0%

Values in ₹ Cr · Source: Screener.in

Balance Sheet

ItemMar 2026Mar 2025Mar 2024Mar 2023
Liabilities
Equity Capital
₹32 Cr
▲0.0%
₹32 Cr
▲0.0%
₹32 Cr
▲0.0%
₹32 Cr
Reserves
₹1.3K Cr
▲624.5%
₹-249 Cr
▼367.7%
₹93 Cr
▼80.6%
₹480 Cr
Borrowings
₹559 Cr
▲107.8%
₹269 Cr
▲341.0%
₹61 Cr
▲281.3%
₹16 Cr
Other Liabilities
₹273 Cr
▼3.9%
₹284 Cr
▼13.4%
₹328 Cr
▲8.6%
₹302 Cr
Total Liabilities
₹2.2K Cr
▲546.1%
₹336 Cr
▼34.8%
₹515 Cr
▼38.0%
₹830 Cr
Assets
Fixed Assets
₹157 Cr
▲58.6%
₹99 Cr
▼8.3%
₹108 Cr
▲1.9%
₹106 Cr
CWIP
₹0 Cr
▼100.0%
₹54 Cr
▲22.7%
₹44 Cr
▲63.0%
₹27 Cr
Investments
₹0 Cr
₹0 Cr
▼100.0%
₹2 Cr
▼99.3%
₹291 Cr
Other Assets
₹2.0K Cr
▲1000.5%
₹183 Cr
▼49.4%
₹362 Cr
▼10.8%
₹406 Cr
Total Assets
₹2.2K Cr
▲546.1%
₹336 Cr
▼34.8%
₹515 Cr
▼38.0%
₹830 Cr

Values in ₹ Cr · Source: Screener.in

Cash Flow Statement

ItemMar 2026Mar 2025Mar 2024Mar 2023
Operating CF
₹-239 Cr
▲33.6%
₹-360 Cr
▲16.1%
₹-429 Cr
▼521.7%
₹-69 Cr
Investing CF
₹-24 Cr
▼115.2%
₹158 Cr
▼59.7%
₹392 Cr
▲171.5%
₹-548 Cr
Financing CF
₹261 Cr
▲31.2%
₹199 Cr
▲373.8%
₹42 Cr
▼93.2%
₹617 Cr
Net Cash Flow
₹-1 Cr
▲66.7%
₹-3 Cr
▼160.0%
₹5 Cr
▲600.0%
₹-1 Cr
Free Cash Flow
₹-262 Cr
▲29.2%
₹-370 Cr
▲18.7%
₹-455 Cr
▼441.7%
₹-84 Cr

Values in ₹ Cr · Source: Screener.in

Key Ratios History

MetricMar 2026Mar 2025Mar 2024Mar 2023
Debtor Days
2d
▼97.6%
82d
▲9.3%
75d
▲50.0%
50d
Inventory Days
Days Payable
Cash Conv. Cycle
2d
▼97.6%
82d
▲9.3%
75d
▲50.0%
50d
Working Capital Days
215d
▲112.1%
-1780d
▼141.2%
-738d
▼282.4%
-193d
ROCE
164.0%
▲158.8%
-279.0%
▼158.3%
-108.0%

Source: Screener.in · Lower days = better efficiency

Frequently Asked Questions

What is Sun Pharma Advanced Research Company Limited share price today?
Sun Pharma Advanced Research Company Limited (SPARC) is currently trading at ₹224.52 on NSE, down 1.31% as of the last market session. Prices update daily after market close on MarketNetra.
Is Sun Pharma Advanced Research Company Limited available in F&O (Futures & Options)?
Yes, Sun Pharma Advanced Research Company Limited (SPARC) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Sun Pharma Advanced Research Company Limited 52-week high and low?
Sun Pharma Advanced Research Company Limited's 52-week high is ₹289 and the 52-week low is ₹108. The current price of ₹224.52 is 22.3% below the 52W high.
What is Sun Pharma Advanced Research Company Limited P/E ratio?
Sun Pharma Advanced Research Company Limited's current P/E ratio is 4.88. This indicates the market is paying ₹4.88 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Sun Pharma Advanced Research Company Limited options?
Sun Pharma Advanced Research Company Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade SPARC options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.